Year: 2011 
Title: Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14 
Authors: Pritchard KI;Shepherd LE;Chapman JA;Norris BD;Cantin J;Goss PE;Dent SF;Walde D;Vandenberg TA;Findlay B;O'Reilly SE;Wilson CF;Han L;Piura E;Whelan TJ;Pollak MN; 
Reference: Journal of Clinical Oncology 2011 Oct 10; 29 (29) 
Link: http://jco.ascopubs.org/content/29/29/3869.abstract 

Year: 2006 
Title: Urokinase plasminogen activator is a serum marker for breast cancer recurrence: a nested case-control pilot study by the National Cancer Institute of Canada 
Authors: Dos Santos N;Chapman J;Andrews H;Meng D;Shepherd L;Pollak M;Li D;Wilson C;Dunn S; 
Reference: Breast Cancer Research and Treatment 2006 Dec 14; 100 (Suppl 1, abstr 1010) 
Link:  

Year: 2006 
Title: Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for post menopausal women in NCIC CTG MA.14 adjuvant breast cancer trial 
Authors: Pollak MN;Chapman JW;Shepherd L;Meng D;Richardson P;Wilson C;Orme B;Pritchard KI; 
Reference: Journal of Clinical Oncology 2006 Jun 2 ; 24 (18s Part 1, abstr 524) 
Link: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=32856 

Year: 2008 
Title: Use of elevated bone turnover to predict bone metastasis 
Authors: Lipton A;Chapman JW;Demers L;Shepherd LE;Han L;Wilson CF;Pritchard KI;Leitzel K;Ali SM;Pollak MN; 
Reference: Journal of Clinical Oncology 2008 May 30; 26 (15s Part 1, abstr 591) 
Link: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35823 

Year: 2008 
Title: NCIC-CTG MA14 trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer 
Authors: Pollak MN;Chapman JW;Pritchard KI;Krook JE;Dhaliwal HS;Vandenberg TA;Norris BD;Whelan TJ;Wilson CF;Shepherd LE; 
Reference: Journal of Clinical Oncology 2008 May 30; 26 (15s Part 1, abstr 532) 
Link: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33132 

Year: 2009 
Title: Examination of TIMP-1 levels and relapse-free survival for patients in NCIC CTG MA.14 who received adjuvant tamoxifen +/- octreotide LAR 
Authors: Ali SM;Chapman JW;Lipton A;Leitzel K;Pritchard KI;Pu X;Wilson C;Carney WP;Shepherd L;Pollak M; 
Reference: Cancer Research 2009 Dec 15; 69 (24 Suppl 3, abstr 3022) 
Link: http://cancerres.aacrjournals.org/cgi/content/abstract/69/24_MeetingAbstracts/3022 

Year: 2009 
Title: Elevated bone resorption predicts shorter recurrence-free survival for bone metastasis in breast cancer 
Authors: Lipton A;Chapman JW;Demers L;Shepherd L;Han L;Wilson CF;Pritchard KI;Leitzel K;Ali SM;Pollak M; 
Reference: The Breast Journal 2009 Mar 11; 18 (Suppl 1, abstr 68) 
Link:  

Year: 2009 
Title: Serum 1-OH vitamin D and prognosis of postmenopausal breast cancer patients: NCIC-CTG MA14 trial 
Authors: Piura E;Chapman JW;Lipton A;Zhu L;Leitzel K;Wilson CF;Pritchard KI;Shepherd L;Pollak MN; 
Reference: Journal of Clinical Oncology 2009 May 29; 27 (15s Part 1, abstr 534) 
Link: http://meetinglibrary.asco.org/content/34242-65 

Year: 2009 
Title: Effect of adjuvant chemotherapy on bone resorption marker beta C-telopeptide in post-menopausal women 
Authors: Ali SM;Chapman JW;Demers L;Shepherd L;Han L;Wilson C;Pritchard K;Leitzel K;Pollak M;Lipton A; 
Reference: Journal of Clinical Oncology 2009 May 29; 27 (15s Part 1, abstr 594) 
Link: http://meetinglibrary.asco.org/content/34757-65 

Year: 2010 
Title: Serum SDF-1: biomarker of bone relapse in the NCIC MA.14 adjuvant breast cancer trial 
Authors: Ali SM;Aguilar-Mahecha A;Chapman JW;Lipton A;Leitzel K;Jahan K;Hassan S;Shepherd LE;Han L;Wilson CF;Pritchard KI;Pollak MN;Basik M; 
Reference: Cancer Research 2010 Dec 8 ; 70 (24 Suppl, abstr P4-09-09) 
Link: http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_1230 

Year: 2010 
Title: Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer 
Authors: Basik M;Aguilar-Mahecha A;Chapman JW;Jahan K;Hassan S;Han L;Wilson CF;Pritchard KI;Shepherd LE;Pollak MN; 
Reference: Journal of Clinical Oncology 2010 Jun 4 ; 28 (15s, abstr 551) 
Link: http://meetinglibrary.asco.org/content/52912-74 

Year: 2011 
Title: Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer 
Authors: Aguilar-Mahecha A;Basik M;Chapman JW;Jahan K;Hassan S;Zhu L;Wilson CF;Pritchard KI;Shepherd LE;Pollak MN; 
Reference: Journal of Clinical Oncology 2011 Jun 3 ; 29 (suppl; abstr 577) 
Link: http://meetinglibrary.asco.org/content/80472-102 

Year: 2011 
Title: Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14 
Authors: Lipton A;Chapman JA;Demers L;Shepherd LE;Han L;Wilson CF;Pritchard KI;Leitzel KE;Ali SM;Pollak M; 
Reference: Journal of Clinical Oncology 2011 Sep 20; 29 (27) 
Link: http://jco.ascopubs.org/content/29/27/3605.abstract 

Year: 2016 
Title: Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study 
Authors: Sgroi D;Chapman JA;Badovinac-Crnjevic T;Zarella E;Binns S;Zhang Y;Schnabel C;Erlander M;Pritchard K;Han L;Shepherd L;Goss P;Pollak M; 
Reference: 2016 Jan 4 ; 18 (1) 
Link: http://breast-cancer-research.com/content/18/1/1 

Year: 2016 
Title: Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14 
Authors: Chapman JA;Sgroi DC;Goss PE;Zarella E;Binns S;Zhang Y;Schnabel CA;Erlander MG;Pritchard KI;Han L;Badovinac-Crnjevic T;Shepherd LE;Pollak MN; 
Reference: Breast Cancer Research and Treatment 2016 May 1 ; 157 (1) 
Link: http://dx.doi.org/10.1007/s10549-016-3806-z